WO2004037221A1 - Method for cosmetic body treatment to enhance the silhouette and to develop the female bust, and double-acting cosmetic composition therefor - Google Patents
Method for cosmetic body treatment to enhance the silhouette and to develop the female bust, and double-acting cosmetic composition therefor Download PDFInfo
- Publication number
- WO2004037221A1 WO2004037221A1 PCT/FR2003/003045 FR0303045W WO2004037221A1 WO 2004037221 A1 WO2004037221 A1 WO 2004037221A1 FR 0303045 W FR0303045 W FR 0303045W WO 2004037221 A1 WO2004037221 A1 WO 2004037221A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- product
- extract
- lipolytic
- hand
- breast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- Cosmetic body treatment method for improving the silhouette and development of the female bust, and binary cosmetic composition for its implementation is a cosmetic body treatment method for improving the silhouette and development of the female bust, and binary cosmetic composition for its implementation.
- the invention relates to a method of cosmetic treatment of the body to improve the silhouette, and / or to develop parts of the bust such as the breasts.
- the subject of the invention is also a binary cosmetic composition or cosmetic complex consisting of two products, the joint use of which has the effect of increasing the volume of areas deemed to be too small or of too small size such as that of the breasts, while decreasing the volume of an area deemed too large, for example that of the hips.
- estrogenic hormones or phytoestrogens can be considered but poses a potential risk and is prohibited in cosmetics in certain countries (list of substances whose use in cosmetic products and personal care products is subject to ban on Annex II of the modified Cosmetic Directive 76/768 / EEC: estrogens and substances with effect).
- Fat synthesis promoters have been proposed (JP-11199499) to allow breast augmentation.
- This solution which is better than the previous ones, however has the drawback of increasing the total fat mass of the person using it, which is not generally sought after. Efficiency is also low, and is reduced to the ability of breast tissue to synthesize this fat.
- the binary composition according to the invention used according to the treatment method according to the invention turns out to be of a definite advantage for solving problems such as those disproportionate breasts (one breast larger than the other).
- the lipolytic product is applied to the larger breast and / or the hips and the other product to the smaller breast.
- the present invention therefore relates to a method of cosmetic treatment of the body intended to improve the silhouette, characterized in that, on the one hand, it is applied to a first zone the volume of which is to be reduced (for example the hips or the breast the largest in the case of disproportionate breasts), a product with lipolytic properties in order to cause lipolysis of the fats contained in the adipocytes of the tissues concerned (such as the hips, ...), and, on the other hand, on a second zone, the volume of which is to be increased (for example the breast or breasts), a product endowed with lipogenetic properties so as to effect a capture and a fixation, in said second zone, of the fats released by the application of the lipolytic product.
- a first zone the volume of which is to be reduced (for example the hips or the breast the largest in the case of disproportionate breasts)
- a product with lipolytic properties in order to cause lipolysis of the fats contained in the adipocytes of the tissues concerned (such as the hip
- the present invention relates to a method of cosmetic treatment of the body intended to develop the bust, by applying on the one hand on an adipose zone of the body, a product endowed with lipolytic properties in order to cause a lipolysis of the fats contained in the adipocytes of the tissues of the zone concerned, and on the other hand, on the part or parts of the bust that l 'We wish to develop a product endowed with lipogenetic properties or an ability to capture the fats released by the application of the lipolytic product and to fix them in said parts of the bust.
- the present invention also relates to a binary cosmetic composition or cosmetic complex for the implementation of this process, consisting on the one hand, of a product endowed with lipolytic properties intended to be applied to an adipose area of the body, and d 'on the other hand, of a product endowed with lipogenetic properties or an ability to capture fats and to fix them, intended to be applied on the part or parts of the bust which one wishes to develop.
- the cosmetic complex according to the invention causes, on the one hand, lipolysis of the fats contained in the adipocytes of the tissues, preferably those of the hips (the presence of which is generally abundant at this level in women, and considered unsightly), and , on the other hand, a capture and fixation of the fats thus released, preferably at the breasts to increase the volume.
- the product having lipolytic properties preferably, although in no way limiting, contains xanthines, and in particular caffeine or even alpha-tocopherol nicotinate, cola extract, carnitine, vitamin E and its acetate, blockers of alpha 2 receptor such as Ginkgo biloba, inhibitors of NPY receptors such as Enteromorpha compressa extract and any other lipolytic agent capable of releasing fat from adipocytes.
- oily plant extracts including: • Climbing ivy extract (Hedera helix), for example obtained by prolonged maceration of the leaves in propylene glycol;
- Arnica extract (Arnica montana L), for example obtained by maceration of arnica flower heads in glycol or in apricot kernel oil
- Rosemary extract (Rosmarinus officinalis N), for example obtained by prolonged maceration of the leaves in glycol or apricot kernel oil
- Marigold extract Calendule officinalis, for example obtained by prolonged maceration of flowers in glycol or apricot kernel oil;
- St. John's wort extract for example obtained from flowers by maceration in neutral oil or in glycol;
- the extract of fragon for example obtained from rhizomes of fragon (Ruscus aculeatus L), previously ground and extracted using an aqueous-alcoholic solution of an alcohol having 3 to 6 carbon atoms preferably in l using water-saturated n-butanol;
- Ulmaire extract (Filipendula ulmaria L), for example obtained by prolonged maceration of the whole plant in neutral oil or in isopropyl myristate; • Orthosiphon extract (Ortosifon stamincus benth), for example obtained by prolonged maceration of flower heads in neutral oil;
- the algae extract for example obtained by prolonged maceration of the whole plant in an oxyethylenated oil
- water-soluble plant extracts including: The water-soluble extract of algae, hydroglycolic extract obtained, by for example, by prolonged maceration of fronds in a solution of hydroglycolic extract;
- the water-soluble birch extract (Betula alba) obtained, for example, by prolonged maceration of bark in a solution of hydroglycolic extract;
- hydro-alcoholic plant extracts including the hydro-alcoholic extract of cola nuts (Cola Nipida), for example obtained by leaching seeds with alcohol;
- the product intended to capture and fix the fats released after lipolysis, or “lipogenetic” product preferably contains, although in no way limiting, adenosine and / or vitamin A and / or Pro-retinol and / or Ginseng like any other another substance capable of retaining fat in breast adipocytes, among which there may be mentioned insulin-like substances or any factor of the IGF type (insulin growth factor).
- the cosmetic complex according to the invention can be in different forms, in particular in the form of an oil-in-water emulsion.
- the lipogenetic product is composed of:
- Macadamia oil 0.5 g
- this product is composed of:
- Carboxypolymethylene or Carboxylic polymer 0.40 g - Diethanolamine cetyl phosphate 1.50 g
- Macadamia oil 0.50 g
- Ginseng extract (Ginseng panax) 0.20 g
- Carbopol 981 (marketed by Goodrich) 0.2 g - Triethanolamine 0.2 g
- Ginseng extract 0.5 g
- Fragon glycine (Ruscus aculeatus) 1 g - Demineralized water qs 100 g
- the above embodiments can advantageously be used on the breasts in order to increase the volume.
- the following embodiment can be applied to all zones whose volume must be increased:
- Orthosifon extract (Ortosifon stamincus) 1 g
- one embodiment of the product with lipolytic property contains:
- Keto-stearyl alcohol 1.50 g
- Preservative 0.30 g
- Carbopol 981 (marketed by Goodrich) 0.6 g
- the above embodiments can advantageously be used on the hips in order to reduce the volume.
- the following embodiment can be applied to any zone whose volume must be reduced:
- This method allows each volunteer to position themselves, for each of the criteria concerned, on a continuous analog scale, unstructured, materialized by a 10 cm line, and comprised between two opposite qualitative criteria.
- the products are distributed to volunteers who apply them once or twice a day, for four weeks at the level of the bust for the lipogenetic product and at the level of the thighs, belly and hips for the lipolytic product. They are instructed to wash their hands thoroughly between the application of the two products.
- the results are expressed by the average of the measurements in cm of the position of the criterion on the given axis.
- volume volume, firmness, hold, slimming, stomach, silhouette and cellulite.
- the embodiment of the invention described below is particularly preferred for the treatment of disproportionate breasts (lipolytic product on the large breast and lipogenetic product on the small breast).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
Abstract
Description
Procédé de traitement cosmétique du corps pour l'amélioration de la silhouette et le développement du buste féminin, et composition cosmétique binaire pour sa mise en œuvre.Cosmetic body treatment method for improving the silhouette and development of the female bust, and binary cosmetic composition for its implementation.
L'invention se rapporte à un procédé de traitement cosmétique du corps pour améliorer la silhouette, et/ou pour développer des parties du buste telles que les seins.The invention relates to a method of cosmetic treatment of the body to improve the silhouette, and / or to develop parts of the bust such as the breasts.
L'invention a également pour objet une composition cosmétique binaire ou complexe cosmétique constitué de deux produits dont l'utilisation conjointe a pour effet d'augmenter le volume de zones jugées trop réduites ou de taille trop modeste comme par exemple celle des seins, tout en diminuant le volume d'une zone jugée trop importante, par exemple celui des hanches.The subject of the invention is also a binary cosmetic composition or cosmetic complex consisting of two products, the joint use of which has the effect of increasing the volume of areas deemed to be too small or of too small size such as that of the breasts, while decreasing the volume of an area deemed too large, for example that of the hips.
L'usage de dérivé animal ou végétal pour provoquer une tension de la peau du buste est connu (FR 2 296 425). L'amélioration apportée est cependant fugace et plutôt mécanique ou indirecte par des effets astringents ou de stimulation de la circulation sanguine locale.The use of animal or plant derivative to cause tension in the skin of the bust is known (FR 2 296 425). The improvement made is however fleeting and rather mechanical or indirect through astringent effects or stimulation of local blood circulation.
L'usage d'hormones œstrogeniques ou de phytoœstrogènes peut être envisagé mais présente un risque potentiel et est interdit en cosmétique dans certains pays (liste des substances dont l'emploi dans les produits cosmétiques et les produits d'hygiène corporelle est soumis à interdiction de l'annexe II de la Directive cosmétique 76/768/CEE modifiée : œstrogènes et substances à effet).The use of estrogenic hormones or phytoestrogens can be considered but poses a potential risk and is prohibited in cosmetics in certain countries (list of substances whose use in cosmetic products and personal care products is subject to ban on Annex II of the modified Cosmetic Directive 76/768 / EEC: estrogens and substances with effect).
Des composés organiques différents ont été décrits (EP-0281647) mais agissent plutôt comme des prothèses.Different organic compounds have been described (EP-0281647) but rather act as prostheses.
Des promoteurs de synthèse de graisse ont été proposés (JP-11199499) pour permettre l'augmentation mammaire. Cette solution meilleure que les précédentes a cependant l'inconvénient d'augmenter la masse de graisse totale de la personne qui l'utilise ce qui n'est pas en général recherché. L'efficacité est également faible, et est réduite à la capacité du tissu mammaire à synthétiser cette graisse.Fat synthesis promoters have been proposed (JP-11199499) to allow breast augmentation. This solution, which is better than the previous ones, however has the drawback of increasing the total fat mass of the person using it, which is not generally sought after. Efficiency is also low, and is reduced to the ability of breast tissue to synthesize this fat.
Des recherches et expérimentations conduites par l'auteur de la présente invention ont permis de constater que l'application, sur les hanches ou autres zones adipeuses de la partie inférieure du tronc ou du corps, d'un produit cosmétique ayant pour effet de stimuler localement la lipolyse, associée à l'application sur le buste d'un second produit cosmétique ayant pour effet de capter et de fixer les graisses ainsi libérées, permettait d'obtenir un développement notable des seins sans risque d'effet secondaire. De plus, le volume disgracieux des hanches du sujet se trouve réduit de ce que la poitrine a gagné, ce qui est un avantage supplémentaire pour la silhouette.Research and experiment conducted by the author of the present invention have shown that the application, on the hips or other fatty areas of the lower part of the trunk or of the body, of a cosmetic product having the effect of locally stimulating lipolysis, associated with the application to the bust of a second cosmetic product having the effect of capturing and fixing the fats thus released, made it possible to obtain a noticeable development of the breasts without risk of side effect. In addition, the unsightly volume of the subject's hips is reduced by what the chest has gained, which is an additional advantage for the silhouette.
Outre le développement des seins de taille trop modeste, il a également été constaté que la composition binaire selon l'invention utilisée selon le procédé de traitement selon l'invention, s'avérait être d'un avantage certain pour solutionner des problèmes tels que ceux des poitrines disproportionnées (un des seins plus volumineux que l'autre). Dans ce cas le produit lipolytique est appliqué sur le sein le plus gros et / ou sur les hanches et l'autre produit sur le sein le plus petit.In addition to the development of breasts that are too modest in size, it has also been found that the binary composition according to the invention used according to the treatment method according to the invention, turns out to be of a definite advantage for solving problems such as those disproportionate breasts (one breast larger than the other). In this case the lipolytic product is applied to the larger breast and / or the hips and the other product to the smaller breast.
La présente invention se rapporte donc à un procédé de traitement cosmétique du corps destiné à améliorer la silhouette, caractérisé en ce que l'on applique d'une part sur une première zone dont on veut diminuer le volume (par exemple les hanches ou le sein le plus volumineux dans le cas de poitrines disproportionnées), un produit doté de propriétés lipolytiques afin de provoquer une lipolyse des graisses contenues dans les adipocytes des tissus concernés (tel que les hanches, ...), et, d'autre part, sur une deuxième zone dont on veut augmenter le volume (par exemple le ou les seins), un produit doté de propriétés lipogénétiques de sorte à réaliser un captage et une fixation, dans ladite deuxième zone, des graisses libérées par l'application du produit lipolytique.The present invention therefore relates to a method of cosmetic treatment of the body intended to improve the silhouette, characterized in that, on the one hand, it is applied to a first zone the volume of which is to be reduced (for example the hips or the breast the largest in the case of disproportionate breasts), a product with lipolytic properties in order to cause lipolysis of the fats contained in the adipocytes of the tissues concerned (such as the hips, ...), and, on the other hand, on a second zone, the volume of which is to be increased (for example the breast or breasts), a product endowed with lipogenetic properties so as to effect a capture and a fixation, in said second zone, of the fats released by the application of the lipolytic product.
Plus particulièrement, la présente invention se rapporte à un procédé de traitement cosmétique du corps destiné à développer le buste, par l'application d'une part sur une zone adipeuse du corps, un produit doté de propriétés lipolytiques afin de provoquer une lipolyse des graisses contenues dans les adipocytes des tissus de la zone concernée, et d'autre part, sur la ou les parties du buste que l'on désire développer, un produit doté de propriétés lipogénétiques ou d'une capacité à capter les graisses libérées par l'application du produit lipolytique et à les fixer dans lesdites parties du buste.More particularly, the present invention relates to a method of cosmetic treatment of the body intended to develop the bust, by applying on the one hand on an adipose zone of the body, a product endowed with lipolytic properties in order to cause a lipolysis of the fats contained in the adipocytes of the tissues of the zone concerned, and on the other hand, on the part or parts of the bust that l 'We wish to develop a product endowed with lipogenetic properties or an ability to capture the fats released by the application of the lipolytic product and to fix them in said parts of the bust.
La présente invention se rapporte également à une composition cosmétique binaire ou complexe cosmétique pour la mise en œuvre de ce procédé, constituée d'une part, d'un produit doté de propriétés lipolytiques destiné à être appliqué sur une zone adipeuse du corps, et d'autre part, d'un produit doté de propriétés lipogénétiques ou d'une capacité à capter les graisses et à les fixer, destiné à être appliqué sur la ou les parties du buste que l'on désire développer.The present invention also relates to a binary cosmetic composition or cosmetic complex for the implementation of this process, consisting on the one hand, of a product endowed with lipolytic properties intended to be applied to an adipose area of the body, and d 'on the other hand, of a product endowed with lipogenetic properties or an ability to capture fats and to fix them, intended to be applied on the part or parts of the bust which one wishes to develop.
Le complexe cosmétique selon l'invention provoque, d'une part, une lipolyse des graisses contenues dans les adipocytes des tissus, de préférence ceux des hanches (dont la présence est généralement abondante à ce niveau chez les femmes, et jugée disgracieuse), et, d'autre part, un captage et une fixation des graisses ainsi libérées, de préférence au niveau des seins pour en augmenter le volume.The cosmetic complex according to the invention causes, on the one hand, lipolysis of the fats contained in the adipocytes of the tissues, preferably those of the hips (the presence of which is generally abundant at this level in women, and considered unsightly), and , on the other hand, a capture and fixation of the fats thus released, preferably at the breasts to increase the volume.
Le produit présentant des propriétés lipolytiques contient de façon préférentielle quoique nullement limitative, des xanthines, et notamment la caféine ou encore le nicotinate d'alpha-tocophérol, l'extrait de cola, la carnitine, la vitamine E et son acétate, des bloqueurs de récepteur alpha 2 comme le Ginkgo biloba, des inhibiteurs des récepteurs NPY comme l'extrait de Enteromorpha compressa ainsi que tout autre agent lipolytique capable de libérer les graisses des adipocytes.The product having lipolytic properties preferably, although in no way limiting, contains xanthines, and in particular caffeine or even alpha-tocopherol nicotinate, cola extract, carnitine, vitamin E and its acetate, blockers of alpha 2 receptor such as Ginkgo biloba, inhibitors of NPY receptors such as Enteromorpha compressa extract and any other lipolytic agent capable of releasing fat from adipocytes.
Pour ces agents lipolytiques, on peut citer :For these lipolytic agents, there may be mentioned:
les extraits végétaux huileux dont : • L'extrait de lierre grimpant (Hedera hélix), par exemple obtenu par macération prolongée des feuilles dans du propylène glycol ;oily plant extracts including: • Climbing ivy extract (Hedera helix), for example obtained by prolonged maceration of the leaves in propylene glycol;
• L'extrait d'arnica (Arnica montana L), par exemple obtenu par macération des capitules floraux d'arnica dans du glycol ou dans de l'huile de noyaux d'abricot; • L'extrait de romarin (Rosmarinus officinalis N), par exemple obtenu par macération prolongée des feuilles dans du glycol ou de l'huile de noyaux d'abricot;• Arnica extract (Arnica montana L), for example obtained by maceration of arnica flower heads in glycol or in apricot kernel oil; • Rosemary extract (Rosmarinus officinalis N), for example obtained by prolonged maceration of the leaves in glycol or apricot kernel oil;
• L'extrait de souci (Calendule officinalis), par exemple obtenu par macération prolongée des fleurs dans du glycol ou de l'huile de noyaux d'abricot;• Marigold extract (Calendule officinalis), for example obtained by prolonged maceration of flowers in glycol or apricot kernel oil;
• L'extrait de sauge (Salvia officinalis L), par exemple obtenu par macération prolongée des feuilles dans du glycol ou de l'huile de noyaux d'abricot;• Sage extract (Salvia officinalis L), for example obtained by prolonged maceration of the leaves in glycol or apricot kernel oil;
• L'extrait de millepertuis (Hypericum perforatum), par exemple obtenu à partir des fleurs par macération dans une huile neutre ou dans glycol;• St. John's wort extract (Hypericum perforatum), for example obtained from flowers by maceration in neutral oil or in glycol;
• L'extrait de fragon par exemple obtenu à partir de rhizomes de fragon (Ruscus aculeatus L), préalablement broyés et extraits à l'aide d'une solution hydroalcoolique d'un alcool ayant de 3 à 6 atomes de carbone de préférence à l'aide de n-butanol saturé d'eau ;• The extract of fragon, for example obtained from rhizomes of fragon (Ruscus aculeatus L), previously ground and extracted using an aqueous-alcoholic solution of an alcohol having 3 to 6 carbon atoms preferably in l using water-saturated n-butanol;
• L'extrait d'ulmaire (Filipendula ulmaria L), par exemple obtenu par macération prolongée de la plante entière dans une huile neutre ou dans du myristate d'isopropyle; • L'extrait d'orthosiphon (Ortosifon stamincus benth), par exemple obtenu par macération prolongée des capitules floraux dans une huile neutre;• Ulmaire extract (Filipendula ulmaria L), for example obtained by prolonged maceration of the whole plant in neutral oil or in isopropyl myristate; • Orthosiphon extract (Ortosifon stamincus benth), for example obtained by prolonged maceration of flower heads in neutral oil;
• L'extrait d'algues par exemple obtenu par macération prolongée de la plante entière dans une huile oxyéthylénée• The algae extract, for example obtained by prolonged maceration of the whole plant in an oxyethylenated oil
les extraits végétaux hydrosolubles dont : L'extrait hydrosoluble d'algues, extrait hydroglycolique obtenu, par exemple, par macération prolongée de thalles dans une solution d'extrait hydroglycolique;water-soluble plant extracts including: The water-soluble extract of algae, hydroglycolic extract obtained, by for example, by prolonged maceration of fronds in a solution of hydroglycolic extract;
• L'extrait hydrosoluble de lierre grimpant (Hedera hélix) obtenu, par exemple, par macération prolongée de feuilles et de tiges dans une solution d'extrait hydroglycolique;• The water-soluble climbing ivy extract (Hedera helix) obtained, for example, by prolonged maceration of leaves and stems in a solution of hydroglycolic extract;
• L'extrait hydrosoluble de bouleau (Betula alba) obtenu, par exemple, par macération prolongée d'écorce dans une solution d'extrait hydroglycolique;• The water-soluble birch extract (Betula alba) obtained, for example, by prolonged maceration of bark in a solution of hydroglycolic extract;
- les extraits végétaux hydro-alcooliques dont l'extrait hydroalcoolique de noix de cola (Cola Nipida), par exemple obtenu par lixiviation de graines à l'alcool ;- hydro-alcoholic plant extracts, including the hydro-alcoholic extract of cola nuts (Cola Nipida), for example obtained by leaching seeds with alcohol;
Le produit destiné à capter et fixer les graisses libérées après lipolyse, ou produit "lipogénetique" contient de façon préférentielle quoique nullement limitative de l'adénosine et/ou de la vitamine A et/ou du Pro-rétinol et/ou du Ginseng comme toute autre substance capable de retenir les graisses dans les adipocytes mammaires parmi lesquelles on peut citer les substances insuline-like ou tout facteur de type IGF (insuline growth factor).The product intended to capture and fix the fats released after lipolysis, or “lipogenetic” product preferably contains, although in no way limiting, adenosine and / or vitamin A and / or Pro-retinol and / or Ginseng like any other another substance capable of retaining fat in breast adipocytes, among which there may be mentioned insulin-like substances or any factor of the IGF type (insulin growth factor).
Le complexe cosmétique selon l'invention peut se présenter sous différentes formes, en particulier sous la forme d'une émulsion huile dans eauThe cosmetic complex according to the invention can be in different forms, in particular in the form of an oil-in-water emulsion.
(H/E) ou eau dans huile (E/H) ayant l'aspect d'une crème ou d'un lait ou sous forme d'un gel et également sous forme de vésicules lipidiques constituées de lipides ioniques (liposomes) ou de lipides non ioniques.(O / W) or water in oil (W / O) having the appearance of a cream or milk or in the form of a gel and also in the form of lipid vesicles consisting of ionic lipids (liposomes) or non-ionic lipids.
Selon un premier mode de réalisation de l'invention, le produit lipogénetique est composé de :According to a first embodiment of the invention, the lipogenetic product is composed of:
- Acrylate C10-30 0,50 g- Acrylate C10-30 0.50 g
Adénosine 0,01 gAdenosine 0.01 g
Ethoxydiglycol 5,00 g Extrait de ginseng 0,20 gEthoxydiglycol 5.00 g Ginseng extract 0.20 g
Alcool 2,00 gAlcohol 2.00 g
Rétinyl palmitate 0,01 gRetinyl palmitate 0.01 g
Carbomère 0.126 g - Butylène glycol 0,24 gCarbomer 0.126 g - Butylene glycol 0.24 g
EDTA 0.005 gEDTA 0.005 g
Conservateur 0.867 gPreservative 0.867 g
Huile de macadamia 0.5 gMacadamia oil 0.5 g
Lécithine hydrogénée 0.09 g - Cyclométhicone 0,20 gHydrogenated lecithin 0.09 g - Cyclomethicone 0.20 g
TEA 99% 0,62 gTEA 99% 0.62 g
Extrait de soja 5,00 gSoy extract 5.00 g
Colorants 0,0002 gDyes 0.0002 g
Eau déminéralisée qsp 100 gDemineralized water qs 100 g
Selon un second mode de réalisation, ce produit est composé de :According to a second embodiment, this product is composed of:
Carboxypolyméthylène ou bien Polymère carboxylique 0.40 g - Diéthanolamine cétyl phosphate 1.50 gCarboxypolymethylene or Carboxylic polymer 0.40 g - Diethanolamine cetyl phosphate 1.50 g
Octyl dodecanol 5.50 gOctyl dodecanol 5.50 g
Alcool cétylique 1 gCetyl alcohol 1 g
Huile minérale 2.00 gMineral oil 2.00 g
Acide stéarique 1 g - Alcool stérylique éthoxylé (20E) 0.30 gStearic acid 1 g - Ethoxylated steryl alcohol (20E) 0.30 g
Alcool céto-stéarylique 1.80 gKeto-stearyl alcohol 1.80 g
Conservateur 0.15 gPreservative 0.15 g
Huile de macadamia 0.50 gMacadamia oil 0.50 g
Triéthanolamine 0.60 g - Cyclométhicone 12 gTriethanolamine 0.60 g - Cyclomethicone 12 g
Diméthicone copolyol 3.00 gDimethicone copolyol 3.00 g
Phenyl Triméthicone 2.00 g Glycine soja 5.00 gPhenyl Trimethicone 2.00 g Soy wisteria 5.00 g
Sépigel 305 1.00 gSepigel 305 1.00 g
Adénosine 0.20 gAdenosine 0.20 g
Butylène glycol 6.00 g - Mica et dioxyde de titane 1.00 gButylene glycol 6.00 g - Mica and titanium dioxide 1.00 g
Extrait de Ginseng (Ginseng panax) 0.20 gGinseng extract (Ginseng panax) 0.20 g
Extrait de lierre grimpant (Hedera helix) 1 gClimbing ivy extract (Hedera helix) 1 g
Eau déminéralisée qsp 100 gDemineralized water qs 100 g
Trois autres exemples de réalisation sont également exposés ci-après :Three other examples of embodiment are also set out below:
1/Emulsion H/E:1 / O / W emulsion:
Paraffine liquide 6 gLiquid paraffin 6 g
Lanoline liquide 3 g - Arlacel 165 (commercialisé par Atlas) 6 gLiquid lanolin 3 g - Arlacel 165 (marketed by Atlas) 6 g
Tween 60 (commercialisé par Atlas) 2 gTween 60 (marketed by Atlas) 2 g
Alcool cétylique 1.2 gCetyl alcohol 1.2 g
Acide stéarique 2.5 gStearic acid 2.5 g
Rétinyl palmitate 0.5 g - Huile de silicone volatile 10 gRetinyl palmitate 0.5 g - Volatile silicone oil 10 g
Triéthanolamine 0.1 gTriethanolamine 0.1 g
Conservateur 0.3 gPreservative 0.3 g
Antioxydants 0.3 gAntioxidants 0.3 g
Adénosine 0.3 g - Extrait de Gingeng 5 gAdenosine 0.3 g - Gingeng extract 5 g
Extrait de Sauge (Salvia officinalis L) 1 gSage extract (Salvia officinalis L) 1 g
Eau déminéralisée qsp 100 gDemineralized water qs 100 g
2/ Crème aux liposomes :2 / Liposome cream:
Huile de tournesol 35 gSunflower oil 35 g
Alcool cétylique 4 g B-sitostérol 4 gCetyl alcohol 4 g B-sitosterol 4 g
Dicétyl phosphate 0.5 gDiketyl phosphate 0.5 g
Conservateur 0.3 gPreservative 0.3 g
Carbopol 981 (commercialisé par Goodrich) 0.2 g - Triéthanolamine 0.2 gCarbopol 981 (marketed by Goodrich) 0.2 g - Triethanolamine 0.2 g
Sphingosine 0.05 gSphingosine 0.05 g
Adénosine 1 gAdenosine 1 g
Extrait de Ginseng 0.5 gGinseng extract 0.5 g
Glycine de fragon (Ruscus aculeatus) 1 g - Eau déminéralisée qsp 100 gFragon glycine (Ruscus aculeatus) 1 g - Demineralized water qs 100 g
Les modes de réalisation ci-dessus peuvent avantageusement être utilisés sur les seins afin d'en augmenter le volume. Le mode de réalisation ci-après peut être appliqué sur toutes zones dont le volume doit être augmenté :The above embodiments can advantageously be used on the breasts in order to increase the volume. The following embodiment can be applied to all zones whose volume must be increased:
Emulsion E/H :W / O emulsion:
Protégin (commercialisépar Goldschmidt) 19 gProtein (sold by Goldschmidt) 19 g
Glycérine 3 gGlycerin 3 g
Huile de vaseline 8 g - Sulfate de Mg 0.5 gVaseline oil 8 g - Mg sulfate 0.5 g
Adénosine 0.5 gAdenosine 0.5 g
Extrait de Ginseng 3 gGinseng extract 3 g
Extrait d'orthosifon (Ortosifon stamincus) 1 gOrthosifon extract (Ortosifon stamincus) 1 g
Rétinyl palmitate 0.02 g - Conservateur 0.2 gRetinyl palmitate 0.02 g - Preservative 0.2 g
Eau déminéralisée qsp 100 gDemineralized water qs 100 g
Selon l'invention, un mode de réalisation du produit à propriété lipolytique contient :According to the invention, one embodiment of the product with lipolytic property contains:
Acrylate C10-30 0,50 g Carboxyméthyl de méthylsilanol 8,00 gAcrylate C10-30 0.50 g Methylsilanol carboxymethyl 8.00 g
Ethoxydiglycol 5,00 gEthoxydiglycol 5.00 g
Acide salicylique 0,444 gSalicylic acid 0.444 g
Caféine 2,20 g - Extrait d'Entéromorphia compressa 1,00 gCaffeine 2.20 g - Enteromorphia compressa extract 1.00 g
Carbomère 0.126 gCarbomer 0.126 g
Butylène glycol 0,24 gButylene glycol 0.24 g
EDTA 0.005 gEDTA 0.005 g
Conservateur 0.30 g - Huile de macadamia 0.5 gPreservative 0.30 g - Macadamia oil 0.5 g
Lécithine hydrogénée 0.09 gHydrogenated lecithin 0.09 g
Cyclométhicone 0,20 gCyclomethicone 0.20 g
TEA 99% 1,12 gTEA 99% 1.12 g
Extrait de Ginkgo biloba 0,75 g - Extrait de Chrysanthellum indicum 0,05 gGinkgo biloba extract 0.75 g - Chrysanthellum indicum extract 0.05 g
Colorants 0,0001 gDyes 0.0001 g
Eau déminéralisée qsp 100 gDemineralized water qs 100 g
Nous citons ci-après d'autres exemples de réalisation du produit lipolytiqueWe cite below other examples of realization of the lipolytic product.
Exemple 1 :Example 1:
- Carboxypolyméthylène 0.40 g- Carboxypolymethylene 0.40 g
Diéthanolamine cétyl phosphate 1.50 gDiethanolamine cetyl phosphate 1.50 g
Octyl dodecanol 5.50 gOctyl dodecanol 5.50 g
Alcool cétylique 1.00 gCetyl alcohol 1.00 g
Huile minérale 3.00 g - Acide stéarique 1.00 gMineral oil 3.00 g - Stearic acid 1.00 g
Alcool stérylique éthoxylé (20E) 0.30 gEthoxylated steryl alcohol (20E) 0.30 g
Alcool céto-stéarylique 1.50 g Conservateur 0.30 gKeto-stearyl alcohol 1.50 g Preservative 0.30 g
Huile de macadamia 1.00 gMacadamia oil 1.00 g
Triéthanolamine 0.60 gTriethanolamine 0.60 g
Cyclométhicone 13.0 g - Diméthicone copolyol 1.00 gCyclomethicone 13.0 g - Dimethicone copolyol 1.00 g
Phenyl Triméthicone 2.00 gPhenyl Trimethicone 2.00 g
Extrait de Ginkgo biloba 0.75 gGinkgo biloba extract 0.75 g
Extrait d'algue 1.00 gSeaweed extract 1.00 g
Caféine 2.00 g - Méthylsilanol carboxyméthyl théophylline alginate 8.00 gCaffeine 2.00 g - Methylsilanol carboxymethyl theophylline alginate 8.00 g
Eau déminéralisée qsp 100 gDemineralized water qs 100 g
Exemple 2:Example 2:
Emulsion gel H/E :O / W gel emulsion:
Carbopol 981 (commercialisé par Goodrich) 0.6 gCarbopol 981 (marketed by Goodrich) 0.6 g
Alcool éthylique 15 gEthyl alcohol 15 g
Huile de silicone volatile 3 gVolatile silicone oil 3 g
Huile de purcellin 7 g - Conservateur 0.3 gPurcellin oil 7 g - Preservative 0.3 g
Caféine anhydre 1 gAnhydrous caffeine 1 g
Parfum 0.4 gPerfume 0.4 g
Extrait d'algue 2 gSeaweed extract 2 g
Triéthanolamine 0.2 g - Extrait de chrysanthellium indicum 1 g0.2 g triethanolamine - Chrysanthemum indicum extract 1 g
Eau déminéralisée qsp 100 gDemineralized water qs 100 g
Exemple 3:Example 3:
Crème aux liposomes :Liposome cream:
Huile de tournesol 35 gSunflower oil 35 g
Alcool cétylique 4 g B-sitostérol 4 gCetyl alcohol 4 g B-sitosterol 4 g
Dicétyl phosphate 0.5 gDiketyl phosphate 0.5 g
Conservateur 0.3 gPreservative 0.3 g
Parfum 0.6 g - Carbopol 981 (commercialisé par Goodrich) 0.2 gPerfume 0.6 g - Carbopol 981 (marketed by Goodrich) 0.2 g
Triéthanolamine 0.2 g0.2 g triethanolamine
Sphingosine 0.05 gSphingosine 0.05 g
Caféine 3 gCaffeine 3 g
Méthylsilanol carboxyméthyl théophylline alginate 4 g - Ginkgo biloba 2 gMethylsilanol carboxymethyl theophylline alginate 4 g - Ginkgo biloba 2 g
Eau déminéralisée qsp 100 gDemineralized water qs 100 g
Les modes de réalisation ci-dessus peuvent avantageusement être utilisés sur les hanches afin d'en diminuer le volume. Le mode de réalisation ci-après peut être appliqué sur toutes zones dont le volume doit être réduit :The above embodiments can advantageously be used on the hips in order to reduce the volume. The following embodiment can be applied to any zone whose volume must be reduced:
Emulsion EIH:EIH emulsion:
Protégin (commercialisépar Goldschmidt) 19 g - Glycérine 3 gProtein (marketed by Goldschmidt) 19 g - Glycerin 3 g
Huile de vaseline 8 gVaseline oil 8 g
Sulfate de Mg 0.5 gMg sulfate 0.5 g
Parfum 0.8 gPerfume 0.8 g
Caféine 0.5 g - Extrait d'Enteromorpha compressa 2 gCaffeine 0.5 g - Enteromorpha compressa extract 2 g
Conservateur 0.2 gPreservative 0.2 g
Eau déminéralisée qsp 100 gDemineralized water qs 100 g
L'efficacité des exemples selon l'invention a été analysée par une étude sensorielle sur échelles analogiques pendant quatre semaines avec 114 sujets, sur l'amélioration de la forme et de l'esthétique générale du buste et des hanches. Cette auto-évaluation fait appel à une technique de cotation couramment utilisée dans ce type d'In Use Test : la technique de cotation sur échelle analogique non structurée.The effectiveness of the examples according to the invention was analyzed by a sensory study on analog scales for four weeks with 114 subjects, on the improvement of the shape and general aesthetics of the bust and hips. This self-assessment uses a scoring technique commonly used in this type of In Use Test: the scoring technique on an unstructured analog scale.
Cette méthode permet à chaque volontaire de se positionner, pour chacun des critères concernés, sur une échelle analogique continue, non structurée, matérialisée par une ligne de 10 cm, et comprise entre deux critères qualitatifs opposés.This method allows each volunteer to position themselves, for each of the criteria concerned, on a continuous analog scale, unstructured, materialized by a 10 cm line, and comprised between two opposite qualitative criteria.
Les 114 volontaires remplissent ces échelles analogiques avant le début de l'étude (T0) et de nouveau après quatre semaines d'utilisation du produit (T4s).The 114 volunteers complete these analog scales before the start of the study (T0) and again after four weeks of using the product (T4s).
Les produits sont distribués aux volontaires qui les appliquent une à deux fois par jours, pendant quatre semaines au niveau du buste pour le produit lipogénetique et au niveau des cuisses, du ventre et des hanches pour le produit lipolytique. Une consigne leur est donnée : de bien se laver les mains entre l'application des deux produits.The products are distributed to volunteers who apply them once or twice a day, for four weeks at the level of the bust for the lipogenetic product and at the level of the thighs, belly and hips for the lipolytic product. They are instructed to wash their hands thoroughly between the application of the two products.
Les résultats sont exprimés par la moyenne des mesures en cm de la position du critère sur l'axe donné.The results are expressed by the average of the measurements in cm of the position of the criterion on the given axis.
Dans le cas présent, les sept critères suivants seront pris en compte : volume, fermeté, tenue, minceur, ventre, silhouette et cellulite.In the present case, the following seven criteria will be taken into account: volume, firmness, hold, slimming, stomach, silhouette and cellulite.
Le test t de Student par paires a été utilisé lors de l'étude statistique. Test pour les SeinsStudent's t-test in pairs was used in the statistical study. Breast test
Test pour les HanchesTest for the Hips
S: Significatif.S: Significant.
Le mode de réalisation de l'invention décrit ci-après est particulièrement préféré pour le traitement des poitrines disproportionnées (produit lipolytique sur le gros sein et produit lipogénetique sur le petit sein).The embodiment of the invention described below is particularly preferred for the treatment of disproportionate breasts (lipolytic product on the large breast and lipogenetic product on the small breast).
Produit à appliquer sur le sein le plus volumineux Emulsion E/H:Product to apply on the largest breast W / O emulsion:
Protégin (commercialisé par Goldschmidt) 19 gProtein (marketed by Goldschmidt) 19 g
Glycérine 3 g - Huile de vaseline 8 gGlycerin 3 g - Vaseline oil 8 g
Sulfate de Mg 0.5 gMg sulfate 0.5 g
Parfum 0.8 gPerfume 0.8 g
Caféine 2 gCaffeine 2 g
Extrait de Chrysanthellium indicum 3 g - Conservateur 0.2 gChrysanthellium indicum extract 3 g - Preservative 0.2 g
Eau déminéralisée qsp 100 gDemineralized water qs 100 g
Produit à appliquer sur le sein le plus petitProduct to be applied to the smallest breast
Emulsion E/H :W / O emulsion:
Protégin (commercialisé par Goldschmidt) 19 gProtein (marketed by Goldschmidt) 19 g
Glycérine 3 gGlycerin 3 g
Huile de vaseline 8 g - Sulfate de Mg 0.5 gVaseline oil 8 g - Mg sulfate 0.5 g
Adénosine 0.02 gAdenosine 0.02 g
Extrait de Ginseng 4 gGinseng extract 4 g
Rétinyl palmitate 0.001gRetinyl palmitate 0.001g
Conservateur 0.2 g - Eau déminéralisée qsp 100 gPreservative 0.2 g - Demineralized water qs 100 g
Conseil d'utilisation :Using advice :
• Bien se laver les mains entre l'application des deux produits sur chacun les deux seins.• Wash your hands well between the application of the two products on each of the two breasts.
Faire bien pénétrer les deux emulsions pour éviter tout mélange entre les produits. Let the two emulsions penetrate well to avoid any mixing between the products.
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03778395A EP1551365A1 (en) | 2002-10-18 | 2003-10-15 | Method for cosmetic body treatment to enhance the silhouette and to develop the female bust, and double-acting cosmetic composition therefor |
| AU2003285404A AU2003285404A1 (en) | 2002-10-18 | 2003-10-15 | Method for cosmetic body treatment to enhance the silhouette and to develop the female bust, and double-acting cosmetic composition therefor |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0212999A FR2845912B1 (en) | 2002-10-18 | 2002-10-18 | BINARY COSMETIC COMPOSITION FOR THE DEVELOPMENT OF THE FEMALE BUST AND THE IMPROVEMENT OF THE SILHOUETTE |
| FR02/12999 | 2002-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004037221A1 true WO2004037221A1 (en) | 2004-05-06 |
Family
ID=32050516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FR2003/003045 Ceased WO2004037221A1 (en) | 2002-10-18 | 2003-10-15 | Method for cosmetic body treatment to enhance the silhouette and to develop the female bust, and double-acting cosmetic composition therefor |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1551365A1 (en) |
| AU (1) | AU2003285404A1 (en) |
| FR (1) | FR2845912B1 (en) |
| RU (1) | RU2005115101A (en) |
| WO (1) | WO2004037221A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012052685A1 (en) | 2010-10-19 | 2012-04-26 | Brigitte Gourlaouen | Product for treating cellulite, skin ageing and for preventing inflammatory processes |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060134234A1 (en) | 2004-12-17 | 2006-06-22 | L'oreal | Cosmetic composition |
| FR2879448B1 (en) * | 2004-12-17 | 2007-01-26 | Oreal | SLIMMING COMPOSITION COMPRISING A XANTHIC BASE, A COPOLYOL DIMETHICONE AND A POLYURETHANE POWDER |
| FR2950528B1 (en) * | 2009-09-29 | 2011-10-28 | Oreal | SLIMING COMPOSITION |
| FR2988601B1 (en) * | 2012-04-02 | 2015-04-03 | Lucas Meyer Cosmetics | USE OF HIF1-ALPHA ACTIVATORS IN COSMETIC COMPOSITIONS FOR PERFORMING LIPOMODELING |
| CN113260423B (en) * | 2018-10-26 | 2024-10-29 | 伊万·加拉宁 | Topical compositions and methods for promoting optimal skin white adipose tissue compositions in vivo |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992011838A1 (en) * | 1991-01-14 | 1992-07-23 | L'oreal | Utilization of a growth factor in a slimming composition |
| US5194259A (en) * | 1990-11-28 | 1993-03-16 | L'oreal | Slimming composition based on ginkgo biloba as an alpha-2-blocker |
| EP0685229A1 (en) * | 1995-06-01 | 1995-12-06 | Shiseido Company Limited | Skin cosmetic composition |
| EP1038518A1 (en) * | 1999-03-22 | 2000-09-27 | L'oreal | SLIMMING COMPOSITION containing a hydrosoluble film-forming polymer |
| US6261603B1 (en) * | 1999-05-11 | 2001-07-17 | Mcelwain Elizena A. | Skin cream |
| JP2001302494A (en) * | 2000-04-26 | 2001-10-31 | Johnson & Johnson Consumer France Sas | Composition including retinoid for skin care and caffeine |
-
2002
- 2002-10-18 FR FR0212999A patent/FR2845912B1/en not_active Expired - Fee Related
-
2003
- 2003-10-15 EP EP03778395A patent/EP1551365A1/en not_active Ceased
- 2003-10-15 WO PCT/FR2003/003045 patent/WO2004037221A1/en not_active Ceased
- 2003-10-15 RU RU2005115101/14A patent/RU2005115101A/en not_active Application Discontinuation
- 2003-10-15 AU AU2003285404A patent/AU2003285404A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194259A (en) * | 1990-11-28 | 1993-03-16 | L'oreal | Slimming composition based on ginkgo biloba as an alpha-2-blocker |
| WO1992011838A1 (en) * | 1991-01-14 | 1992-07-23 | L'oreal | Utilization of a growth factor in a slimming composition |
| EP0685229A1 (en) * | 1995-06-01 | 1995-12-06 | Shiseido Company Limited | Skin cosmetic composition |
| EP1038518A1 (en) * | 1999-03-22 | 2000-09-27 | L'oreal | SLIMMING COMPOSITION containing a hydrosoluble film-forming polymer |
| US6261603B1 (en) * | 1999-05-11 | 2001-07-17 | Mcelwain Elizena A. | Skin cream |
| JP2001302494A (en) * | 2000-04-26 | 2001-10-31 | Johnson & Johnson Consumer France Sas | Composition including retinoid for skin care and caffeine |
Non-Patent Citations (1)
| Title |
|---|
| DATABASE WPI Derwent World Patents Index; AN 2002-158439, XP002271909, "Redusing lipidemia involves administering composition comprising retinoid and caffeine to skin" * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012052685A1 (en) | 2010-10-19 | 2012-04-26 | Brigitte Gourlaouen | Product for treating cellulite, skin ageing and for preventing inflammatory processes |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2845912A1 (en) | 2004-04-23 |
| EP1551365A1 (en) | 2005-07-13 |
| RU2005115101A (en) | 2005-10-27 |
| AU2003285404A1 (en) | 2004-05-13 |
| FR2845912B1 (en) | 2006-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2056322C (en) | Ginkgo biloba acting as alpha-2-blocker slimming compound | |
| EP3348255B1 (en) | Extracts of tetraselmis sp. for cosmetic and therapeutic purposes | |
| BE1009622A3 (en) | Hygiene and cosmetic preparations for prevention and treatment of skin diseases and a method for preparing. | |
| JPH06506668A (en) | Use of growth factors in slimming compositions | |
| CA2136706C (en) | Process for controlling adiposity and compositions for use therein | |
| FR2970868A1 (en) | PLANT ORIGIN EXTRACT, COMPOSITION CONTAINING THE SAME, PROCESS FOR OBTAINING BY VEGETABLE CULTURE AND USES IN THE COSMETIC, PHARMACEUTICAL AND COSMECEUTICAL FIELDS | |
| JP2020529420A (en) | New cosmetic use of Nepherium rappaceum extract | |
| FR2695318A1 (en) | Topical composition intended for the rejuvenation of the skin. | |
| JP2000229834A (en) | Cosmetic | |
| FR2826579A1 (en) | COSMETIC COMPOSITION CONTAINING AT LEAST ONE OIL EXTRACTED FROM CUCURBITACEOUS SEEDS, ITS COSMETIC, THERAPEUTIC AND FOOD USE | |
| WO2014085876A1 (en) | Cosmetic composition | |
| WO2010112084A1 (en) | Topical cosmetic compositions for treating or preventing cellulite | |
| Pavan et al. | Formulation and Evaluation of herbal hair oil | |
| WO2015132501A1 (en) | Skin-brightening cosmetic composition | |
| EP1551365A1 (en) | Method for cosmetic body treatment to enhance the silhouette and to develop the female bust, and double-acting cosmetic composition therefor | |
| KR100761660B1 (en) | Hair growth promoting composition | |
| FR3015285A1 (en) | FORMULATION FOR THE TREATMENT OF HAIR | |
| WO2005094776A1 (en) | Cosmetic or dermatological compositions and applications thereof | |
| FR2880278A1 (en) | USE OF OIL AND PROTEINS EXTRACTED FROM PLUKENETIA VOLUBILIS LINNEO SEEDS IN COSMETIC, DERMATOLOGICAL AND NUTRACEUTICAL PREPARATIONS | |
| JPH11315007A (en) | Collagen productive promoter and preparation for external use for skin | |
| JP2000109417A (en) | Cosmetic for improving somber color | |
| CN108403588A (en) | Natural Plant & Animal Moisturizer | |
| WO2023180661A1 (en) | Cosmetic or dermatological use of an extract of dendrobium officinale for maintaining and/or increasing the thickness of the skin | |
| FR2801789A1 (en) | Compositions comprise keratolin, a lipogenesis inhibitor and excipients for topical application, have a slimming effects on the face | |
| FR2717082A1 (en) | Microemulsion for cosmetic and dermatological use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 167934 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003778395 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2005115101 Country of ref document: RU Kind code of ref document: A |
|
| WWP | Wipo information: published in national office |
Ref document number: 2003778395 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
| WWR | Wipo information: refused in national office |
Ref document number: 2003778395 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2003778395 Country of ref document: EP |